CA
TNGX icon

Cliff Asness’s Tango Therapeutics TNGX Stock Holding History

Cliff Asness’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.85M Sell
91,029
-16,257
-15% -$402K ﹤0.01% 2384
2026
Q1 		$2.24M Buy
107,286
+25,053
+30% +$349K ﹤0.01% 2269
2025
Q4 		$729K Buy
82,233
+3,058
+4% +$26.3K ﹤0.01% 2719
2025
Q3 		$665K Buy
79,175
+229
+0.3% +$1.55K ﹤0.01% 2663
2025
Q2 		$404K Sell
78,946
-63,162
-44% -$156K ﹤0.01% 2723
2025
Q1 		$195K Buy
+142,108
New +$349K ﹤0.01% 2897
2024
Q4 		– Sell
-14,206
Closed -$109K – 2956
2024
Q3 		$109K Sell
14,206
-6,445
-31% -$61.5K ﹤0.01% 2646
2024
Q2 		$177K Sell
20,651
-30,323
-59% -$234K ﹤0.01% 2441
2024
Q1 		$405K Buy
50,974
+28,798
+130% +$309K ﹤0.01% 2036
2023
Q4 		$220K Buy
+22,176
New +$192K ﹤0.01% 2182
2022
Q4 		– Sell
-22,030
Closed -$80K – 2277
2022
Q3 		$80K Buy
+22,030
New +$94.1K ﹤0.01% 2122

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Cliff Asness's TNGX Position: Q2 2026 in Review

Cliff Asness reduced its Tango Therapeutics (TNGX) stake by 15% in Q2 2026, selling an estimated $402K and leaving 91,029 shares worth $2.85M. The position accounts for ﹤0.01% of the portfolio, ranked #2384.

Cliff Asness first reported a position in TNGX in Q3 2022 and has held it in 11 quarters since. 246 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Cliff Asness held 91,029 shares of Tango Therapeutics worth $2.85M as of Q2 2026.
  • Cliff Asness sold 16,257 Tango Therapeutics shares in Q2 2026, an estimated $402K.
  • Tango Therapeutics made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #2384 holding.
  • Cliff Asness first reported a position in Tango Therapeutics in Q3 2022 and has held it in 11 quarters since.
  • 246 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.